Adherence and Acceptability of Once Daily Lamivudine and Abacavir in Human Immunodeficiency Virus Type-1 Infected Children

Radboud University Medical Centre (Radboudumc), Nymegen, Gelderland, Netherlands
The Pediatric Infectious Disease Journal (Impact Factor: 2.72). 06/2006; 25(6):533-7. DOI: 10.1097/01.inf.0000222415.40563.d4
Source: PubMed


Data on adherence to and acceptability of once daily lamivudine and abacavir are few.
Twenty-four U.K. human immunodeficiency virus type-1 infected children 2-13 years of age participated in the Pediatric European Network for the Treatment of AIDS (PENTA) 13 single arm, open label pharmacokinetic study of twice (every 12 hours) versus once (every 24 hours) daily lamivudine and abacavir. Caregivers were asked to complete an adherence questionnaire at screening, week 0 (switch once daily to twice daily) and weeks 4, 12 and 24. Acceptability was also assessed at screening and week 24.
Fifteen children were taking lamivudine and abacavir as part of their regimens, 8 lamivudine only and 1 abacavir only. After switching to lamivudine/abacavir every 24 hours, 7 (29%) received once daily regimens for all drugs. Twenty-three (96%) caregivers thought that switching to once daily lamivudine/abacavir would make things a lot/a little easier for their child: 17 (71%) thought it was actually easier after switching. Six mothers with children taking a mixture of twice/once daily drugs changed their mind, whereas all mothers of children on once daily regimens agreed that it was a lot easier. Nonadherence (missing doses in the last 3 days) was reported for 8 of 118 (7%) completed questionnaires; missed doses were reported for every drug in the regimen with reasons such as "not at home," "forgot" or "routine different from normal." However, viral loads in all these children remained <100 copies/mL.
Adherence to once daily abacavir/lamivudine was good with no evidence of an association between nonadherence and virologic rebound. Acceptability of once daily drugs was best when the whole regimen was dosed once daily.

Download full-text


Available from: Marthe Le Prevost, Oct 01, 2015
  • Source
    • "Once-daily administration regimens could increase convenience and adherence as LePrevost et al showed with abacavir (ABC) plus 3TC use in children.34 However, the efficacy of once-daily ART is highly dependent on the maintenance of inhibitory concentrations throughout the entire dosing interval.35 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Lopinavir/ritonavir (LPV/r) is considered by many as the first choice protease inhibitor (PI) for children. This co-formulation avoids the need for children to take ritonavir separately to "boost" the levels of lopinavir. LPV/r has high virologic potency, an excellent toxicity profile and a high barrier to the development of viral resistance. However, LPV/r has poor tolerability of the oral suspension (due to the poor taste of ritonavir), difficult dosing requirements and metabolic side effects, especially hyperlipidemia. The new tablet low-dose formulation (100/25 mg) may allow more convenient antiretroviral treatment in children. Novel strategies of LPV/r in childhood could maximize its advantages. For example, infants infected with HIV despite single dose Nevirapine after birth need effective combination antiretroviral treatment. This can be given using a higher dose of LPV/r with therapeutic drug monitoring. Other novel uses include once daily LPV/r regimens in older children and adolescents and lower doses of LPV/r in certain populations, which may decrease hyperlipidemia. Heavily pre-treated children might benefit from a double PI/r regimen which includes LPV/r. The high potency of LPV/r needs to be balanced with convenient regimens, to enhance adherence and decrease toxicity whenever possible. The aim of this review is to discuss the rationale behind these novel strategies of LPV/r use in pediatric antiretroviral treatment as well as their results and limitations.
    HIV/AIDS - Research and Palliative Care 03/2010; 2:59-67.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The treatment of pediatric HIV infection has seen vast improvements in terms of better long-term suppression of HIV replication and subsequent improvements in the longevity and quality of life in children. This has been realized, in part, by development of newer antiretroviral medications, better knowledge about the pharmaco-kinetics of these drugs in children, and improved insight on drug toxicities in children. This review will discuss some of the newer agents that may be available for children in the near future, in addition to new pharmacokinetic and toxicity data that are specific to the pediatric patient. New information on key vaccines that should be administered to children with HIV infection is also discussed.
    Current HIV/AIDS Reports 06/2007; 4(2):93-9. DOI:10.1007/s11904-007-0014-9 · 3.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-adherence reduces the effectiveness of antiretroviral therapy in children attending the paediatric HIV/AIDS clinic at Mulago Hospital, Kampala. To determine the levels of adherence to HAART and identify factors associated with non-adherence. A cross-sectional study of 170 children aged 2-18 years. Adherence to HAART was defined as taking > or =95% of prescribed medication. It was determined using three measures: a 3-day self-report by the caregivers, clinic-based pill counts at enrolment and home-based unannounced pill counts 2-3 weeks later. The 3-day self-reported > or =95% adherence was 89.4% (n=170). Using clinic-based pill counts, 94.1% (n=170) had > or =95% adherence to treatment compared with only 72% (n=164) by unannounced pill counts. When the primary caregiver was the only one who knew the child's serostatus, he/she was three times more likely to be non-adherent (p=0.02, OR 3.34, 95% CI 1.14-9.82). Those who had been hospitalised twice or more before starting HAART were more likely to have > or =95% adherence (p=0.02, OR 0.44, 95% CI 0.20-0.92). The majority of children had good adherence levels when estimated by unannounced pill counts. Disclosing the child's HIV serostatus only to the primary caregiver and having been hospitalised only once or not at all were associated with poor adherence.
    Annals of Tropical Paediatrics International Child Health 06/2007; 27(2):123-31. DOI:10.1179/146532807X192499 · 1.17 Impact Factor
Show more